Table 1 Baseline characteristics of subjects
| Â | NC progression | NC regression | p value |
|---|---|---|---|
(n = 74) | (n = 45) | ||
Age (years) | 66 ± 10 | 67 ± 10 | 0.56 |
Men | 63 (85%) | 36 (80%) | 0.47 |
Body mass index (kg/m2) | 24.7 ± 3.7 | 24.0 ± 2.8 | 0.28 |
Treatment allocation | Â | Â | 0.06 |
Pitavastatin | 41 (55%) | 17 (38%) | Â |
Pravastatin | 33 (45%) | 28 (62%) | Â |
Status of coronary artery desease | Â | Â | 0.05 |
Stable angina pectoris | 47 (64%) | 36 (80%) | Â |
Unstable angina pectoris | 27 (36%) | 9 (20%) | Â |
Target coronary artery | Â | Â | 0.51 |
Left anterior desending | 41 (55%) | 26 (58%) | Â |
Left circumflex | 2 (3%) | 3 (7%) | Â |
Right | 31 (42%) | 16 (36%) | Â |
Type of stent | Â | Â | 0.3 |
Bare metal stent | 15 (20%) | 5 (11%) | Â |
Drug-eluting stent | 59 (80%) | 40 (89%) | Â |
Hypertension | 44 (59%) | 31 (69%) | 0.3 |
Diabetes mellitus | 30 (41%) | 20 (44%) | 0.68 |
Medications | Â | Â | Â |
Aspirin | 72 (97%) | 45 (100%) | 0.7 |
Thienopyridines | 73 (99%) | 45 (100%) | >0.99 |
ACE-Is or ARBs | 37 (50%) | 24 (53%) | 0.72 |
β blockers | 8 (11%) | 5 (11%) | >0.99 |
Calcium channel blockers | 35 (47%) | 25 (56%) | 0.38 |
Insulin | 5 (7%) | 6 (13%) | 0.38 |
Follow-up duration (days) | 224 ± 34 | 231 ± 41 | 0.31 |